As small molecule drugs for Duchenne muscular dystrophy (DMD), antisense oligonucleotides (AONs) have been shown to restore the disrupted reading frame of DMD transcripts by inducing specific exon skipping. This allows the synthesis of largely functional Becker muscular dystrophy (BMD)-like dystrophins and potential conversion of severe DMD into milder BMD phenotypes. Thus far we have used 2 0 -O-methyl phosphorothioate (2OMePS) AONs. Here, we assessed the skipping efficiencies of different AON analogs containing morpholino-phosphorodiamidate, locked nucleic acid (LNA) or peptide nucleic acid (PNA) backbones. In contrast to PNAs and morpholinos, LNAs have not yet been tested as splice modulators. Compared to the most effective 2OMePS AON directed at exon 46, the LNA induced higher skipping levels in myotubes from a human control (85 versus 20%) and an exon 45 deletion DMD patient (98 versus 75%). The morpholinoinduced skipping levels were only 5-6%, whereas the PNA appeared to be ineffective. Further comparative analysis of LNA and 2OMePS AONs containing up to three mismatches revealed that LNAs, while inducing higher skipping efficiencies, show much less sequence specificity. This limitation increases the risk of adverse effects elsewhere in the human genome. Awaiting further improvements in oligochemistry, we thus consider 2OMePS AONs currently the most favorable compounds, at least for targeted DMD exon 46 skipping.
Introduction
Antisense oligonucleotides (AONs) have been reported to modulate pre-mRNA splicing in several studies. 1 For instance, AONs have restored normal splicing by blocking cryptic splice sites, 2, 3 altered the ratio of alternative splicing from malignant to nonmalignant isoforms, 4 and induced exon inclusion for mutated exons that were otherwise skipped. 5 In these studies, the AON treatments aimed at the re-establishment of wild-type mRNA. Recently, AONs have alternatively been used to restore the disrupted reading frame of dystrophin mRNAs in Duchenne muscular dystrophy (DMD) gene therapy studies. DMD patients suffer from severe muscle degeneration due to frame-disrupting mutations in the DMD gene that prematurely abort the synthesis of the dystrophin protein. [6] [7] [8] [9] In contrast, mutations in the DMD gene that do not affect the reading frame generate internally deleted but partly functional dystrophins and result in less severe Becker muscular dystrophy (BMD). 10, 11 AON-induced restoration of the DMD reading frame is based on inducing the skipping of specific exons. This was successfully applied in cultured muscle cells from DMD patients and in the mdx mouse model. [12] [13] [14] [15] [16] [17] [18] [19] High exon skipping levels of up to B90% were achieved, allowing the synthesis of significant levels of BMD-like dystrophins in over 75% of treated cells. 17 These dystrophins located appropriately to the sarcolemma and restored the dystrophin-glycoprotein complex, a strong indication of functional restoration.
The AONs used in these studies contained 2 0 -Omethyl modified ribose molecules to render them RNase-H independent, and a full-length 2 0 -O-methyl phosphorothioate backbone (2OMePS AONs) ( Table 1) . Although 2OMePS AONs have advantages such as increased resistance to nuclease degradation and increased uptake when compared to phosphodiester AONs, disadvantages are that a phosphorothioate backbone is to some extent cytotoxic, and may elicit an immunogenic response. 20, 21 Recent developments in oligochemistry have provided AONs with different biophysical, biochemical and biological properties based on various modifications to the sugar or the backbone of the nucleotides. Modified AON analogs include morpholino-phosphorodiamidates (morpholinos), locked nucleic acids (LNAs) and peptide nucleic acids (PNAs) (reviewed by Manoharan 21 ). In morpholinos, the sugar phosphate backbone of DNA is replaced by morpholino-phosphorodiamidate oligonucleotides (Table 1) . 22, 23 Morpholinos are nontoxic, nuclease resistant, 23 have an increased affinity for RNA and are suggested to disrupt the secondary structure of RNA. 1, 22 On the other hand, morpholinos are uncharged and therefore difficult to transfect. Nonetheless, reasonable to good efficiencies have been obtained with the scrape loading technique or with ethoxylated polyethylenimine (EPEI). 24, 25 Morpholinos have been used, amongst others, to study developmental processes by knocking down genes in zebra fish, 26 and to modulate the splicing of the b-globin gene in vitro and in vivo. 25, 27 Recently, morpholinos have been applied in the mdx mouse model to induce the skipping of the mutated exon 23. 28 The morpholinos were transfected into the cells in combination with a sense oligo (leash) to allow formation of a cationic lipoplex. This morpholino treatment restored the dystrophin synthesis in mdx muscle cells both in vitro and in vivo.
LNAs are DNA analogs that contain a methylene bridge, which connects the 2 0 oxygen of ribose with the 4 0 carbon (Table 1) . This bridge results in a locked 3 0 -endo-conformation, which reduces the conformational flexibility of the ribose. 1 LNAs are nuclease-resistant, nontoxic and have the highest affinity for complementary DNA and RNA yet reported for any DNA analog. 29, 30 This high affinity offers both advantages and disadvantages: LNAs will hybridize very efficiently to their target, but LNAs longer than 15 base pairs (bp) have shown thermally stable self-structuring. Furthermore, full-length LNAs seem to hybridize in a less sequence-specific manner than PNA and 2OMePS AONs. 29, 31 LNAs are negatively charged and cationic lipid polymers are applied for delivery into cells. LNAs have been shown to be potent inhibitors of the expression of a cancer-related gene, 31 but have not earlier been studied as splicing modulators.
In PNAs, the sugar phosphate backbone of DNA is replaced by an achiral polyamide backbone (Table 1) . 32 Compared to the 2OMePS backbone, PNAs have a highly increased affinity for DNA and RNA, are suggested to be more sequence-specific, protease-and nuclease-resistant, and nontoxic even at high concentrations. 1, 33 A drawback of the nonionic nature of PNA is its poor water solubility, which makes it complicated to transfect PNAs. 27, 34 Sazani et al 27, 35 have recently bypassed this problem by coupling four lysine residues to the C-terminus of PNAs. The cationic nature of the lysine highly improved the water solubility and allowed entrance into the cell and nucleus without transfection reagent. PNAs have successfully been used to modulate the splicing of the murine interleukin-5 receptor-a chain in vitro and the b-globin gene in vitro and in vivo. For future clinical studies, the preferred AON analog induces the highest levels of exon skipping at low levels of cytotoxicity. In this study, we have compared the efficacy, efficiency and applicability of morpholino, LNA and PNA AON analogs to those of a previously described 2OMePS AON 16, 37 specific for DMD exon 46 in both control and patient-derived myotubes.
Results
Comparative analysis of AON analogs in human control myotubes
To determine the binding affinity of the different AON analogs (Table 1) to the target pre-mRNA, a gel mobility shift assay was performed. DNA, 2OMePS, morpholino, LNA and PNA AONs were hybridized to a 32 P-labeled exon 46 RNA fragment (Figure 1a) . The DNA, 2OMePS and LNA AONs induced a clear mobility shift, indicating that these analogs are able to bind to the target RNA. No shift was detectable for the morpholino and PNA AONs. This suggested a low affinity of these analogs for the target RNA. However, in previous experiments, we observed that some AONs, while not inducing a notable mobility shift, nevertheless did induce exon skipping (unpublished results). For this reason, we decided to still include the morpholino and PNA AONs in further analyses.
Transfection conditions for the different AON analogs, all carrying a 5 0 fluorescein group, were optimized in human control myotubes (Figure 1b) . Based on the presence of nuclear fluorescent signals, transfection efficiencies were determined to be typically over 80% for the 2OMePS, morpholino and LNA AONs. The PNA transfection efficiencies were generally lower (B60-70%). Notably, in contrast to the 2OMePS, LNA and PNA AONs, which showed most of the fluorescence within the nucleus, the morpholino was also clearly present in the cytoplasm.
Previous experiments revealed that most efficient skipping levels, as detected by RT-PCR, were obtained at a dose of 500 nM of 2OMePS AONs. 17 Here we show that also LNA and, remarkably, morpholino AONs are effective in inducing exon 46 skipping (Figure 1c ). For the morpholino and LNA AONs, concentration series experiments indicated highest skipping efficiencies at doses of 1 mM and 500 nM, respectively. For both analogs, higher concentrations did not result in higher levels of exon 46 skipping (data not shown), but instead induced serious cytotoxic effects for the morpholino AON. Only minimal levels of cytotoxicity were present in myotube cultures transfected with 500 nM of LNA 6 days posttransfection, whereas at that time point severe cell death was observed for 200 nM of the 2OMePS AON (data not shown). Since more units of PEI were applied for LNA transfection, this difference is unlikely due to PEIinduced cytotoxicity. We occasionally observed the skipping of both exons 45 and 46 at low levels in response to high doses of the 2OMePS and LNA AONs Efficiencies of over 80% were obtained for the 2OMePS, the morpholino and the LNA AONs, whereas for the PNAs efficiencies were 60-70%. In contrast to the other AON analogs, the morpholino was also abundant in the cytoplasm. (c) RT-PCR analysis of dystrophin mRNA fragments from unaffected control and DMD patient-derived (DL279.1) myotubes following transfection of the different AON analogs. With the exception of the PNA, exon 46 skipping was detected for each analog, both in patient and control myotubes. The precise skipping of exon 46 was confirmed by sequence analysis (data not shown). The DNA size marker is 100 bp. (d) Quantification of RT-PCR products. The percentage of exon 46 skipping was determined by the ratio of the shorter fragment to the total of transcript fragments, and is shown above each column. The LNA induced highest levels of exon skipping in both unaffected control (85%) and patient-derived (98%) myotubes. The 2OMePS AON was remarkably more efficient in the patient-derived myotubes when compared to the control (75 versus 20%, respectively). The morpholino was only moderately effective (5-6%) both in control and patient-derived myotubes.
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Comparative analysis of AON analogs in patient-derived myotubes
We have previously observed that 2OMePS AONs induced higher levels of exon skipping in patientderived myotubes when compared to control samples. 16, 17 This effect was confirmed here in myotubes derived from a DMD patient (DL279.1) affected by an exon 45 deletion. For this patient, exon 46 skipping generates in-frame transcripts. We observed 75% exon 46 skipping in DL279.1 versus 20% in control myotubes for the 2OMePS AON (Figure 1c and d) . The LNA and morpholino AONs were also able to induce exon skipping (98 and 5%, respectively), whereas the PNA was not (Figure 1c and d) . Similar to the 2OMePS AON, the LNA showed higher skipping levels in DL279.1 when compared to those in control myotubes (98 versus 85%). This effect however was not significant for the morpholino or PNA AONs.
Dose effects and sequence specificity of LNA versus 2OMePS AONs
Since the LNAs induced highest skipping levels, we performed a concentration series to determine the minimally effective dose. RT-PCR (Figure 2a ) and quantitative analysis (Figure 2b) showed that in human control myotubes the efficiency dropped markedly from 97 to 30% at doses lower than 500 nM, and that very low levels of exon 46 skipping (o1%) were detectable at 100 nM. In patient-derived myotubes, however, the levels of exon skipping decreased more gradually at lower doses, with exon 46 skipping levels of 86% detectable at a dose of 300 nM, and still a significant level (10%) at 100 nM (Figure 2a and b) .
We then analyzed the sequence specificity of LNA and 2OMePS AONs in patient myotubes (since they showed higher skipping levels than control myotubes). We studied five different LNAs, which contain one or two mismatches at the 5 0 , 3 0 or center position (LNAmm1-5; Figure 3a) , and one LNA that was shifted in the 3 0 direction of exon 46 (LNA9; Figure 3a) . A gel mobility shift assay revealed that all LNAs were able to bind to the target pre-mRNA (data not shown). The LNAs were then transfected into patient myotubes at a dose of 500 nM. RT-PCR analysis (Figure 3b ) and quantification (Figure 3c) showed that the LNAs containing one or two mismatches at the 3 0 end (LNAmm1 and LNAmm4) were able to induce exon 46 skipping at high levels, comparable to the original 100% complementary LNA8 (71-94 versus 100%), suggesting that LNAs have a poor sequence specificity. The LNA containing a single mismatch in the center (LNAmm2) induced only low levels (8%) of exon skipping, whereas the LNA containing two mismatches in the center (LNAmm5) and the 5 0 mismatched LNA (LNAmm3) did not induce any skipping. LNA9 did not induce exon 46 skipping, even though it is completely homologous to exon 46. We also assessed the effects of lower concentrations of the 3 0 mismatch-containing LNAs, and observed exon skipping at comparably lower levels as with LNA8 (data not shown).
We similarly tested five different 2OMePS oligos containing up to three mismatches when compared to the original 2OMePS oligo in patient myotubes (2OMePSmm1-5; Figure 3d ). In contrast to the LNAs, the 2OMePS AONs containing one or two mismatches at the 3 0 end (2OMePSmm1-2) induced exon 46 skipping at significantly reduced levels when compared to the original oligo (7-17 versus 48%) (Figure 3e and f) . The oligos containing three mismatches at the 3 0 end (2OMePSmm3) or one at the 5 0 end (2OMePSmm4) induced only barely detectable levels (1-2%) of exon skipping, whereas the 2OMePS containing three mismatches dispersed throughout the oligo (2OMePSmm5) was completely unable to induce exon skipping. Transfection experiments and RT-PCR analyses of the mismatched 2OMePS AONs and LNAs were repeated several times and showed reproducible efficiencies. Our results indicate that the 2OMePS AONs have a higher sequence specificity than the LNAs.
Discussion
In our previous studies on antisense-induced exon skipping, 2OMePS AONs were applied. 16, 17, 37 In this study, additional AON analogs were tested for their efficacy, efficiency and applicability in inducing DMD exon 46 skipping in control and DMD patient-derived myotube cultures. Towards future clinical trials, the most optimal AON analog should induce high levels of exon skipping, but also be nontoxic, easy to deliver and, preferably, relatively inexpensive. Out of the four Figure 2 Concentration series of LNA8 in control and patient-derived (DL279.1) myotube cultures. (a) RT-PCR analysis of dystrophin mRNA fragments. Significant levels of exon 46 skipping were observed at each dose tested for the patient (DL279.1), whereas only low levels were detected for a dose of 200 and 100 nM in the human control. In control myotubes, skipping of both exons 45 and 46 was sometimes observed at the highest doses (400 and 500 nM). For some DL279.1 fragments, products slightly larger than the wild-type fragments can be observed. This is due to heteroduplex formation of first and second PCR products. The DNA size marker is 100 bp. (b) Quantification of the RT-PCR fragments showed that the levels of exon skipping decrease considerably at doses below 500 nM for the human control (from 97% at 500 nM to 30% at 400 nM and below 1% at 100 nM), but remain high (86%) at a dose of 300 nM for the patient and still significant (10%) at a 100 nM concentration.
Different AON analogs for exon 46 skipping in DMD
A Aartsma-Rus et al alternative analogs tested here, only LNAs induced higher levels of exon skipping when compared to 2OMePS AONs. The morpholino was less efficient in both patient and control myotubes, whereas the PNA was completely ineffective. For both the LNA and 2OMePS AONs, the levels of exon skipping were higher in patient-derived cells than in control cells. We have observed this effect previously in cells from other DMD patients 17 and hypothesize that it is due to nonsensemediated RNA decay (NMD), which will selectively target the out-of-frame skip-product in control myotubes and thereby negatively influence the relative amount of skip-product. In patient-derived cells, the original out-offrame mRNA is subject to NMD, whereas the in-frame skip-product is not. Another explanation may be that AON-mediated exon skipping is actually enhanced in the patient due to the presence of the deletion that already perturbed local splicing. The levels of morpholino-induced exon skipping were comparable in the patient and control samples (6 versus 5%). Although we expected higher levels for the patient, the morpholinoinduced skipping levels are so low that it may be difficult to detect significant differences. It is also possible that the morpholino has a lower affinity for pre-mRNA of the patient than for wild-type dystrophin pre-mRNA, as a consequence of the exon 45 deletion (eg due to an altered secondary structure).
The gel mobility assay showed no shift for the morpholino and PNA AONs, but despite its apparent low affinity for the target pre-mRNA, the morpholino was able to induce low levels of exon 46 skipping. This may be explained by the fact that the morpholino was hybridized to a sense DNA oligo (a 'leash' allowing EPEI-coupled transfection), which may have interfered with the proper hybridization to the target RNA fragment. After transfection into cells, the leash detaches from the morpholino, which is then free to hybridize to the target RNA. Schmajuk et al 25 found that morpholinos were more effective in restoring the wild-type splicing of the b-globin gene when compared to 2OMePS AONs. However, since we observed fluorescence in both the cytoplasm and the nucleus after morpholino transfections, the low levels of exon skipping may be the result of poor nuclear uptake rather than the low efficiency of the morpholino. Further optimization of the morpholino itself and the leash required for EPEI transfection may thus increase the levels of exon 46 skipping. Indeed, Gebski et al 28 have recently shown that levels of exon 23 skipping in the mdx mouse varied when different leashes were used.
Even though the sequences of the PNA and the LNA analogs are completely identical, the LNA induces high levels of exon 46 skipping, whereas the PNA induces no skipping at all. PNA oligos have been reported to induce higher levels of correctly spliced b-globin mRNA than morpholino and 2OMePS analogs. 27, 35 This indicates that PNA is in fact able to modulate splicing and suggests that the lack of exon 46 skipping in our experiments may result from the inability of our PNA to bind to the specific target RNA sequence, or a poor stability of the PNA-RNA complex. Further experiments may identify PNAs with higher binding affinities to exon 46 target sequences.
LNAs are relatively new AON analogs that have thus far only been applied to inhibit the expression of target genes.
29, 31 We show here that LNAs are also very potent modulators of pre-mRNA splicing. In a series of experiments, the LNA induced exon 46 skipping in 85% of control transcripts and in 98% of transcripts from a DMD patient carrying an exon 45 deletion. In comparison, the 2OMePS AONs previously used induced 20% exon 46 skipping in control cells and 75% skipping in exon 45-deleted transcripts. Notably, the LNA also seemed to be less toxic than 2OMePS AONs.
Based on these results, LNA in principle may be a promising alternative for antisense-induced exon skipping studies. Unfortunately however, due to the shorter sequence (14-mer), it shows complete homology to several other sequences in the human genome. Most of these were located within noncoding regions, either in or near genes. Increasing the length of the LNA to enhance specificity is problematic, since 15-mer LNAs have been reported to show thermally stable self-structuring. 29 In addition, our results with LNAs containing mismatches show that LNAs with one or two mismatches in the 3 0 part of the AON were almost as potent as the specific LNA. This suggests that the binding of only 12 bp is enough to induce the skipping of exon 46, which is not surprising, given the extremely high melting temperatures of LNA (predicted to be 1311C for our 14-mer LNA; Table 1 ). It does, however, imply that our exon 46-specific LNA may also adversely bind to other sequences in the human genome that contain these 12 bp. The LNA may bind to even shorter sequences, since, for instance, a 7-mer still has a predicted melting temperature of over 601C. Furthermore, we have recently injected the human LNA into mouse muscle. With one mismatch in the center of the AON when compared to the mouse sequence, the human LNA yet induced skipping of the murine exon 46, even at low concentrations (data not shown). This again underlined the potential risk for nonsequence-specific effects associated with LNAs. To decrease the affinity for RNA, chimeric LNA/2 0 -Omethyl RNA oligos have been generated. 38 These chimeras have lower melting temperatures than fulllength LNA, but still have higher affinities for RNA than 2OMePS AONs. In fact, chimeric LNAs have been shown to block transcription of the HIV-1 transactivating responsive element in vitro. 38 Our results with mismatched 2OMePS AONs show that these analogs are more sequence specific than the LNAs. The presence of one mismatch at the 3 0 end results in an almost three-fold decrease of exon 46 skipping levels, whereas no exon skipping was left with 2OMePS AONs containing three 3 0 mismatches. One might have anticipated a greater effect of a single mismatch in the shorter 14-mer LNA than in the longer 20-mer 2OMePS AON. However, the opposite was found true for the 3 0 end. Furthermore, for both the LNA and the 2OMePS analogs, mismatches at the 3 0 end induced higher levels of exon 46 skipping than those at the 5 0 end or in the center of the AONs. This suggests that, whether or not due to the presence of the fluorescent label, mismatches at the 5 0 end reduced the affinity for the target RNA to a larger extent.
By choosing other target sequences within the exon, the levels of exon 46 skipping may be optimized for the PNA and morpholino AONs. Similarly, these analogs may be more effective in inducing the skipping of other DMD exons. This would agree with reports showing that morpholinos and PNAs are more efficient than 2OMePS analogs in inducing the skipping of murine exon 23 or correcting aberrant b-globin splicing, respectively. 27, 28, 35 In other words, for each different target sequence, the best choice of oligochemistry may vary. The relatively wide mutation spectrum in DMD requires the design of a series of efficient AONs targeting different exons. In that respect, we have obtained good results with 2OMePS AONs. By designing only two AONs per exon, we identified at least one efficient AON for 14 out of the 17 exons targeted 37 (unpublished results). Whether or not AON design is as simple using other analogs remains to be established.
Materials and methods

AONs and primers
The characteristics of the AON analogs in this study are reviewed in Table 1 . The 2OMePS AONs (sequences shown in Figure 3d ; Eurogentec, Belgium) have a fulllength phosphorothioate backbone and 2 0 -O-methyl modified ribose molecules, as previously described. 16, 37 The morpholino (Gene-Tools, USA) has a morpholinophosphoroamidate backbone and is linked to a sense DNA oligo for EPEI transfection. The LNAs (sequences shown in Figure 3a ; Proligo, France) have full-length LNA backbones. The PNA (Eurogentec, Belgium) has a PNA backbone and four lysine residues at the C-terminal end to improve water solubility and facilitate transfection into cells. All AONs contain a 5 0 fluorescein group (6-FAM) to confirm nuclear localization of the AONs following transfection. Note that we have previously shown that labeled and nonlabeled 2OMePS AONs were equally efficient in restoring dystrophin synthesis in DMD patient-derived myotube cultures. 17, 18 Gel mobility shift assay Human dystrophin exon 46 RNA was in vitro transcribed as described previously. 16 The binding affinity of the individual AONs (at a dose of 0.5 pmol) was determined by overnight incubation in a hybridization buffer (1 mM Tris-HCl pH 7.4, 50 nM NaCl, 5 mM MgCl 2 ) at 371C, followed by 8% PAGE and PhosphoImager analysis (Molecular Dynamics).
Myogenic cell cultures and transfection
Primary human myoblasts from an unaffected control and a DMD patient (DL279.1; carrying a deletion of exon 45) were isolated from muscle biopsies and cultured as described previously. 37 Myotubes were obtained from confluent myoblast cultures, following 7-14 days of serum deprivation. For the 2OMePS and LNA AONs, PEI was used for transfection, according to the manufacturer's instructions (ExGen500; MBI Fermentas), with 3.5 ml PEI per mg of transfected AON (ie 12.9 ml (70 mM) for the 2OMePS and 9.2 ml (50 mM) for the LNA oligo). EPEI was used to transfect the morpholino AON according to the manufacturer's instructions, with 1 ml of 200 mM EPEI (Gene-Tools, USA) for each 200 nmol of morpholino. PNAs were applied to 1 ml culture medium, without any transfection reagent. At 3 h posttransfection, 2 ml medium was added.
RNA isolation, RT-PCR and sequence analysis
RNA isolation, RT-PCR analysis and direct sequencing were performed as described. 17 Primary PCRs included primers in exon 43 (CCTGTGGAAAGGGTGAAGC) and 48 (CTGAACGTCAAATGGTCCTTC); nested PCRs included primers in exon 44 (CGATTTGACAGATCTGTT GAG) and 47 (GAGCACTTACAAGCACGGG). All primers were synthesized by Eurogentec (Belgium). For quantification, the skip-products were analyzed using the DNA 1000 LabChip s Kit on the Agilent 2100 bioanalyzer (Agilent Technologies, USA).
